摘要
目的检测SFRP1基因在非小细胞肺癌(NSCLC)组织和血浆中的甲基化状态,分析其临床意义。方法留取78例NSCLC患者术中癌组织、正常肺组织及术前血浆标本,25例肺部良性病变组织及50例肺部良性病变患者或健康志愿者血浆标本为对照,甲基化特异性聚合酶链反应(MSP)检测SFRP1基因启动子区甲基化情况,并分析与临床病理特征之间的相关性。结果78例NSCLC组织中,SFRP1基因启动子甲基化比例为32.1%,高于正常组织的7.7%和25例肺部良性病变组织的0(P<0.01);SFRP1基因启动子甲基化与患者淋巴结转移相关(P=0.039)。NSCLC术前血浆DNA中SFRP1甲基化比例为28.2%,高于对照组的4.0%(P<0.01),且血浆DNA甲基化状况与组织中具有良好的一致性。结论血浆DNA中SFRP1甲基化检测可能对NSCLC早期诊断有益。
Objective To detect the promoter methylation status of SFRP1 gene in tissue and plasma DNA of non-small cell lung cancer（NSCLC） patients and evaluate its correlation with clinicopathological features.Methods A total of 78 paired NSCLC specimens and their adjacent normal tissues were collected in the study,as well as the matched 78 preoperative plasma samples,25 specimens from patients with benign pulmonary diseases and 50 plasma samples of benign pulmonary diseases or healthy donors were used as controls.Promoter methylation status of SFRP1 gene was determined by methylation-specific polymerase chain reaction（MSP）,and the correlation between methylation profiles and clinicopathological parameters was statistically analyzed.Results Aberrant methylation of SFRP1 gene was detected in 28 of 78（32.1%） NSCLC tissues,the frequency was significantly higher than that in adjacent normal tissues 7.7% and lung tissues with benign diseases 0（P〈0.01）;SFRP1 hypermethylation was correlated with lymph metastasis in NSCLC tissues（P=0.039）.Moreover,22 of 78（28.2%） plasma samples showed SFRP1 methylation whereas only 2（4.0%） in the plasmas of 50 cancer-free controls（P〈0.01）,and the concordance of SFRP1 methylation status in tumor tissues and corresponding plasma samples was good.Conclusion Detection of SFRP1 methylation in plasma may be benefit for the early diagnosis of NSCLC.
出处
《临床肿瘤学杂志》
CAS
2010年第3期207-210,共4页
Chinese Clinical Oncology
基金
南京军区南京总医院青年基金项目(Q2008027)
